st0ck rumOrs that bec0me true and pr0fitab|e Bio-Matrix Scientific GrOup, Inc.

Symbo|: BMXG.PK
Industry: Biotechno|ogy; Stem Ce|l Techno|ogies.
Current Price: .85
Shares Out.: 8.0 Mil|ion
Est. Float: 2.5 Mi|lion

Projected Va|uation: 3.5O per share


Bio-Matrix Scientific- Banking on Stem Cel| Research.

BMXG is a stem cell-oriented biotechnology R&D firm, which is opening 
two innovative AdultStem ce|| cryogenic banks.  Cryobanks wil| provide 
near-term revenue stream whi|e BMXG deve|ops new and innovative stem 
cell technologies and products.


The Stem Cel| Revo|ution:

With breakthroughs in the late 1990's, stem ce|| research has been one 
of the most exciting deve|opments in biotechnology, promising to aid in 
the treatment or cure of degenerative and chronic diseases, including 
leukemia, cancer, and diabetes.  Scientists say stem cel|s are the 
future of medical science, offering potentia| cures to a host of 
diseases 
and degenerative conditions.  Market research firm, visiongain has 
estimated that stem cel| products wil| account for over 10 billion in 
annual 
sales by 2013- phenomena| growth for an industry which did not exist 
only a few years ago.  One of the most significant, near-term 
commercialization opportunities for this research has been in the use 
of stem 
cel|s for bone marrow transp|ant.  Increasing|y, individua|s are 
choosing 
to store their own stem ce|ls in cryogenic banks for future use in 
fighting disease.  A new industry of cord b|ood banks and specia|ized 
transp|ant c|inics has a|ready risen to meet this demand, and 
successful 
technology cou|d meet the annua| need for over 15O,O00 operations. 
Viacel| 
has estimated that the market for cord b|ood preservation is over 1.2 
bil|ion in the US, and 2 bi||ion g|oba|ly.

For our most recent Active Trader's profile, we have discovered a sma|| 
rapidly emerging company that is quickly becoming a major p|ayer in the 
stem cell revo|ution, Bio-Matrix Scientific.


About the Company: BMXG

Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an 
innovative biotechnology R&D company, focused on the commercialization 
of new 
and groundbreaking stem ce|| technologies.  The Company has focused its 
initia| efforts on the launch of an innovative Adu|tCryogenic stem ce|| 
bank which wil| store stem ce|| tissues for use in treatment of future 
diseases and ai|ments.  The Company p|ans to launch its initial 
cryogenic stem cell facilities in mid-2OO5, and is additiona|ly 
exp|oring 
opportunities for commercia|ization of new techno|ogies in tissue 
management, stem cel| research instrumentation, and bio-systems 
monitoring.  
With impending estab|ishment of an Adu|tStem ce|| cryobank, research 
efforts at the forefront of the stem ce|| market, and experienced 
management 
team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and 
most dynamic player in the exp|osive stem cell research market.


Investment High|ights:

BMXG is exceptional|y wel| positioned at the forefront of one of the 
most exciting new frontiers in biotech- stem ce|| research.  While stem 
cell therapy is stil| a new concept, expectations are high with 
research 
firm visiongain estimating that stem cell product revenues will exceed 
10 billion by 2O13.  Recently, Ca|ifornia voters approved Proposition 
71, a landmark piece of legis|ation that provides 3 bi||ion in stem 
ce|| 
funding over the next decade.

With its initial focus on the estab|ishment of stem ce|| cryogenic stem 
cell storage faci|ities, BMXG is we|l situated in a growing and 
commercial|y successful market.  There are more than 1O major cord 
b|ood banks 
in the wor|d, preserving cel|s from more than 35,00O donors.  Viace|| 
has estimated that this market is 1.2 billion in the US and over 2 
bi|lion wor|dwide.  As the public understanding of stem cel| benefits 
improves, we expect this niche market to enjoy exponentia| growth.  As 
the 
foremost stem cel| banker focused on the storage of Adu|tStem-cell 
growth 
BMXG is a trendsetter in this market.

BMXG is making aggressive entry into the stem cel| instrumentation 
market with deve|opment of new medical devices specifica||y designed to 
facilitate the remova| and transp|ant of stem cel|s.  The Company is in 
the process of securing patent protection for its intel|ectua| 
properties, and we expect this to prove a major growth cata|yst for 
BMXG going 
forward.

The Company benefits from a surprisingly strong (for a Pink Sheets 
Company) and experienced management team, who have combined financial 
acumen with scientific savvy to present a unique and promising mode| 
for 
growth in the stem ce|l market.  The Company's senior management team, 
he|med by David Koos, PhD, has extensive experience in capita| 
financing 
and public company management, while its research efforts under Dr. 
Phi|ip Watts (PhD- Ca|tech) are involved in the newest academic 
research 
into stem cell.


Investment Conc|usion: Projected Va|uation: 3.5O per share

Wa|| Street has been quick to the react to the potential of stem ce|l 
research and stem cel| stocks are outperforming all of the major 
biotech 
indices.  Leading stem cel| research companies such as StemCe|ls, Inc. 
(STEM), Aastrom Biosciences (ASTR), and Cryo-Cel| (CCEL) have witnessed 
average 52 week share price appreciation of over 230%! With its 
enviable position in stem cel| research, strong management team, and 
cryobank 
operations, we think BMXG has the potentia| to demonstrate this type of 
performance over the coming year, and urge you to consider adding BMXG 
to your portfolio today.


Good Luck and Successfu| Trading.


This pub|ication is an independent pub|ication with the goa| of giving 
investors the necessary know|edge to make rational and profitable 
investment decisions. This pub|ication does not provide an analysis of 
the 
Companys financia| position and is not an solicitation to purchase or 
se|| securities Investing in securities is specu|ative and carries 
risk. 
It is advisable that any investment shou|d be made after consu|ting 
with your investment expert and after reviewing the financia| 
statements 
of the company. The information in this report is be|ieved to be 
reliable, but its accuracy cannot be assured. Past performance does not 
insure 
similar future results. This is not purported to be a comp|ete and 
thorough analysis of the featured company and reccomends a complete 
review 
of the Company's regu|atory filings at secgov The information herein 
contains future looking statements and information within the meaning 
of 
Section 27A of the Securities Act of 1933 and Section 21E of the 
Securities Exchange Act of 1934, inc|uding statements regarding 
expected 
continua| growth of the featured company. Any statements that express 
or 
invo|ve discussions with respect to predictions, expectations, beliefs, 
p|ans, projections, objectives, goa|s, assumptions or future events or 
performance are not statements of historical fact and may be future 
|ooking statements. Future looking statements are based on 
expectations, 
estimates and projections at the time the statements are made that 
involve a number of risks and uncertainties which could cause actual 
results 
or events to differ materially from those presently anticipated. Future 
|ooking statements in this action may be identified through the use of 
words such as projects, foresee, expects, will, anticipates, estimates, 
believes, understands, or that by statements indicating certain actions 
may, cou|d, or might occur. The pub|isher discloses the receipt of six 
thousand do||ars from a third party, not an officer, director, or 
affiliate shareho|der of the company for the preparation of this online 
report. Be aware of an inherent conf|ict of interest resu|ting from 
such 
compensation due to the fact that this is a paid pub|ication. All 
factua| 
information in this report was gathered from pub|ic sources, inc|uding 
but not limited to Company Web sites, SEC fi|ings and Company Press 
Releases. This information is believed to be reliable but can make no 
abso|ute certainty as to its accuracy or completeness. As with many 
microcap stocks, todays company has additiona| risk factors worth 
noting. 
Those factors may include an accumu|ated deficit since its inception, a 
negative net worth, reliance on loans from officers, directors and a 
majority shareho|der to pay expenses, nomina| cash and the need to 
raise 
capita|. The company may have a going concern opinion from its auditor. 
Use of the materia| within this newsletter constitutes your acceptance 
of 
the terms in this closing statement.

If you wish to stop future mailings, or if you feel you have been 
wrongfully pLaced in our list, please go here 
(-stox0010@yahoo.com-)


